FDA Issues Serious Liver Injury Warning for Obeticholic Acid

The FDA has issued a warning of serious liver injury for patients taking obeticholic acid (Ocaliva, Intercept) for primary biliary cholangitis, even those without cirrhosis. This notice follows a 2021 contraindication of the medication for patients with PBC and advanced cirrhosis.